Spravato: First FDA-Approved Monotherapy for Treatment-Resistant Depression скачать в хорошем качестве

Spravato: First FDA-Approved Monotherapy for Treatment-Resistant Depression

Treatment-resistant depression (TRD) remains a significant challenge for clinicians and patients alike, often requiring innovative strategies beyond traditional antidepressants. SPRAVATO® was initially approved by the FDA in March 2019 as an adjunct therapy for adults with TRD. In 2025, the FDA extended its approval to include monotherapy for adults with TRD, based on robust clinical evidence demonstrating its efficacy and safety. This marked a pivotal moment, as SPRAVATO® became the first monotherapy specifically designed for TRD. Read our detailed blog post here: https://psychiatryeducationforum.com/... Timestamps: 01:35: History of Esketamine’s FDA approval. 04:00: When to Avoid: Contraindications. 04:43: How to Dose? 07:23: Clinical Studies Supporting Approval. 10:04: Common Adverse Events. 🔔 Don’t forget to like, subscribe, and share for more updates on cutting-edge psychiatry treatments! SUBSCRIBE ‪@PsychiatryEducationForum‬ Dr. Harvinder Singh, a dedicated psychiatry expert and creator of the Psychiatry Education Forum Academy, shares valuable clinical insights to empower busy healthcare professionals with practical psychiatry knowledge. Website: https://psychiatryeducationforum.com Instagram: / psych_edu_forum Facebook: / psychiatryeducationforum #SPRAVATO #Esketamine #treatmentresistantdepression #psychiatryeducation #mentalhealth